What is Theravance Biopharma's revenue?

Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.

Is Theravance Biopharma profitable?

Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.

What are Theravance Biopharma's profit margins?

Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.

What is Theravance Biopharma's earnings per share?

Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.

Where does Theravance Biopharma's income statement data come from?

Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Theravance Biopharma TBPH Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$107.46M+66.9%	$64.38M+12.1%	$57.42M+11.8%	$51.35M-7.2%
Research and development	$37.41M-0.6%	$37.64M-7.3%	$40.62M-35.9%	$63.39M-67.3%
Selling, general and administrative	$73.65M+6.5%	$69.17M-1.3%	$70.1M+4.5%	$67.07M-32.5%
Other operating expenses	$111.07M-0.2%	$111.33M-1.9%	$113.46M-20.8%	$143.3M-54.2%
Total operating expenses	$111.07M-0.2%	$111.33M-1.9%	$113.46M-20.8%	$143.3M-54.2%
Operating income	-$3.6M+92.3%	-$46.95M+16.2%	-$56.04M+39.1%	-$91.96M+64.3%
Operating margin	-3.4%+69.6pp	-72.9%+24.7pp	-97.6%+81.5pp	-179.1%+287pp
Interest expense	$2.46M-3.3%	$2.55M+8.3%	$2.35M-63.1%	$6.37M-77.1%
Other income (expense), net	$10.17M+108%	$4.88M-46.5%	$9.12M+6.7%	$8.55M+671%
Income before income taxes	$129.25M+390%	-$44.61M+9.4%	-$49.27M+46.9%	-$92.82M+62.3%
Income tax expense	$23.35M+97.8%	$11.8M+99.3%	$5.92M—	——
Net income	$105.9M+288%	-$56.42M-2.2%	-$55.19M-106%	$872.13M+537%
Net margin	98.5%+186pp	-87.6%+8.5pp	-96.1%-1,795pp	1,698.5%+2,059pp
Diluted earnings per share	$2.03+277%	-$1.15-18.6%	-$0.97-108%	$11.54+491%
Basic earnings per share	$2.09+282%	-$1.15-18.6%	-$0.97-108%	$11.54+491%
Weighted-average shares, diluted	203.8M+4.6%	194.9M-14.2%	227.3M-24.4%	300.6M+10.0%
Weighted-average shares, basic	200.7M+3.0%	194.9M-14.2%	227.3M-24.4%	300.6M+10.0%
Restructuring And Related Expenses	——	——	——	——
Nonoperating Income Expense Milestone Income	——	——	——	——
Other income, net (Note 6)	$10.17M+108%	$4.88M-46.5%	$9.12M+6.7%	$8.55M+671%
Revenue From Contract With Customer Excluding Assessed Tax	$107.46M+66.9%	$64.38M+12.1%	$57.42M+11.8%	$51.35M-7.2%
EBIT	-$3.6M+92.3%	-$46.95M+16.2%	-$56.04M+39.1%	-$91.96M+64.3%
EBITDA	-$1.98M+95.6%	-$45.24M+16.3%	-$54.03M+38.8%	-$88.24M+65.1%
EBITDA	-$1.98M+95.6%	-$45.24M+16.3%	-$54.03M+38.8%	-$88.24M+65.1%
EBITDA margin	-1.8%+68.4pp	-70.3%+23.8pp	-94.1%+77.8pp	-171.9%+286pp
EBIT	-$3.6M+92.3%	-$46.95M+16.2%	-$56.04M+39.1%	-$91.96M+64.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Theravance Biopharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's revenue?: Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
Is Theravance Biopharma profitable?: Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
What are Theravance Biopharma's profit margins?: Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
What is Theravance Biopharma's earnings per share?: Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
Where does Theravance Biopharma's income statement data come from?: Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.